Randomized controlled experimental study of hydrocortisone and D-cycloserine effects on fear extinction in PTSD
© 2021. This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply..
Fear extinction underlies prolonged exposure, one of the most well-studied treatments for posttraumatic stress disorder (PTSD). There has been increased interest in exploring pharmacological agents to enhance fear extinction learning in humans and their potential as adjuncts to PE. The objective of such adjuncts is to augment the clinical impact of PE on the durability and magnitude of symptom reduction. In this study, we examined whether hydrocortisone (HC), a corticosteroid, and D-Cycloserine (DCS), an N-methyl-D-aspartate receptor partial agonist, enhance fear extinction learning and consolidation in individuals with PTSD. In a double-blind placebo-controlled 3-group experimental design, 90 individuals with full or subsyndromal PTSD underwent fear conditioning with stimuli that were paired (CS+) or unpaired (CS-) with shock. Extinction learning occurred 72 h later and extinction retention was tested one week after extinction. HC 25 mg, DCS 50 mg or placebo was administered one hour prior to extinction learning. During extinction learning, the DCS and HC groups showed a reduced differential CS+/CS- skin conductance response (SCR) compared to placebo (b = -0.19, CI = -0.01 to -37, p = 0.042 and b = -0.25, CI = -08 to -0.43, p = 0.005, respectively). A nonsignificant trend for a lower differential CS+/CS- SCR in the DCS group, compared to placebo, (b = -0.25, CI = 0.04 to -0.55, p = 0.089) was observed at retention testing, one week later. A single dose of HC and DCS facilitated fear extinction learning in participants with PTSD symptoms. While clinical implications have yet to be determined, our findings suggest that glucocorticoids and NMDA agonists hold promise for facilitating extinction learning in PTSD.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:47 |
|---|---|
| Enthalten in: |
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology - 47(2022), 11 vom: 19. Okt., Seite 1945-1952 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Inslicht, Sabra S [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 22.09.2022 Date Revised 06.11.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41386-021-01222-z |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM333370406 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM333370406 | ||
| 003 | DE-627 | ||
| 005 | 20231225221527.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41386-021-01222-z |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1111.xml |
| 035 | |a (DE-627)NLM333370406 | ||
| 035 | |a (NLM)34799682 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Inslicht, Sabra S |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Randomized controlled experimental study of hydrocortisone and D-cycloserine effects on fear extinction in PTSD |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.09.2022 | ||
| 500 | |a Date Revised 06.11.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021. This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply. | ||
| 520 | |a Fear extinction underlies prolonged exposure, one of the most well-studied treatments for posttraumatic stress disorder (PTSD). There has been increased interest in exploring pharmacological agents to enhance fear extinction learning in humans and their potential as adjuncts to PE. The objective of such adjuncts is to augment the clinical impact of PE on the durability and magnitude of symptom reduction. In this study, we examined whether hydrocortisone (HC), a corticosteroid, and D-Cycloserine (DCS), an N-methyl-D-aspartate receptor partial agonist, enhance fear extinction learning and consolidation in individuals with PTSD. In a double-blind placebo-controlled 3-group experimental design, 90 individuals with full or subsyndromal PTSD underwent fear conditioning with stimuli that were paired (CS+) or unpaired (CS-) with shock. Extinction learning occurred 72 h later and extinction retention was tested one week after extinction. HC 25 mg, DCS 50 mg or placebo was administered one hour prior to extinction learning. During extinction learning, the DCS and HC groups showed a reduced differential CS+/CS- skin conductance response (SCR) compared to placebo (b = -0.19, CI = -0.01 to -37, p = 0.042 and b = -0.25, CI = -08 to -0.43, p = 0.005, respectively). A nonsignificant trend for a lower differential CS+/CS- SCR in the DCS group, compared to placebo, (b = -0.25, CI = 0.04 to -0.55, p = 0.089) was observed at retention testing, one week later. A single dose of HC and DCS facilitated fear extinction learning in participants with PTSD symptoms. While clinical implications have yet to be determined, our findings suggest that glucocorticoids and NMDA agonists hold promise for facilitating extinction learning in PTSD | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Research Support, U.S. Gov't, Non-P.H.S. | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 7 | |a Glucocorticoids |2 NLM | |
| 650 | 7 | |a Receptors, N-Methyl-D-Aspartate |2 NLM | |
| 650 | 7 | |a N-Methylaspartate |2 NLM | |
| 650 | 7 | |a 6384-92-5 |2 NLM | |
| 650 | 7 | |a Cycloserine |2 NLM | |
| 650 | 7 | |a 95IK5KI84Z |2 NLM | |
| 650 | 7 | |a Hydrocortisone |2 NLM | |
| 650 | 7 | |a WI4X0X7BPJ |2 NLM | |
| 700 | 1 | |a Niles, Andrea N |e verfasserin |4 aut | |
| 700 | 1 | |a Metzler, Thomas J |e verfasserin |4 aut | |
| 700 | 1 | |a Lipshitz, Sa'ar L |e verfasserin |4 aut | |
| 700 | 1 | |a Otte, Christian |e verfasserin |4 aut | |
| 700 | 1 | |a Milad, Mohammed R |e verfasserin |4 aut | |
| 700 | 1 | |a Orr, Scott P |e verfasserin |4 aut | |
| 700 | 1 | |a Marmar, Charles R |e verfasserin |4 aut | |
| 700 | 1 | |a Neylan, Thomas C |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology |d 1988 |g 47(2022), 11 vom: 19. Okt., Seite 1945-1952 |w (DE-627)NLM012626821 |x 1740-634X |7 nnns |
| 773 | 1 | 8 | |g volume:47 |g year:2022 |g number:11 |g day:19 |g month:10 |g pages:1945-1952 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41386-021-01222-z |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 47 |j 2022 |e 11 |b 19 |c 10 |h 1945-1952 | ||